Combined use of PRAME inhibitors and HDAC inhibitors

Details Combined use of PRAME inhibitors and HDAC inhibitors Combined use of PRAME inhibitors and HDAC inhibitors

2011-04-19

2011-04-19

Chong, Kimberly (Department: 1635)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C536S024500, C536S024310, C536S024100

Reexamination Certificate

active

07928081

ABSTRACT:
The invention relates to the cancer antigen PRAME (PReferentially expressed Antigen in MElanoma) and its use in a method of treatment of a tumour which comprises administering to a subject in need of treatment an effective amount of an inhibitor of PRAME, in combination with a second agent selected from the group of an inhibitor of HDAC (an HDACi) and a retinoid.

REFERENCES:
McCarthy. PRAME in the frame. Nature Reviews Cancer, vol. 5, 2005, p. 839.
Doolan et al. Breast Cancer Res Treat. 2008, vol. 109:359-365).
Tajeddine et al. Cancer Research 2005, vol. 65: 7348-7355.
Epping et al, “A functional genetic screen identifies retinoic acid signaling as a target of histone deacetylase inhibitors”, PNAS, Nov. 6, 2007, vol. 104, No. 45, pp. 17777-17782.
Epping et al, “A functional genetic screen identifies retinoic acid signaling as a target of histone deacetylase inhibitors”, PNAS, Nov. 6, 2007, vol. 104, No. 45, Supporting Figures (5 pages).
Ikeda et al.,Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor, Immunity, vol. 6, No. 2, Feb. 1997, pp. 199-208, XP002216277.
Plumb et al.,Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101, Molecular Cancer Therapeutics, vol. 2, No. 8, Aug. 2003, pp. 721-728, XP002372785.
Freemantle et al.,Retinoids in cancer therapy and chemoprevention: Promise meets resistance, Oncogene, vol. 22, No. 47, Oct. 20, 2003, pp. 7305-7315, XP008061601.
Brummelkamp et al.,Stable Suppression of Tumorigenicity by Virus-Mediated RNA Interference, Cancer Cell, vol. 2, No. 3, Sep. 2002, pp. 243-247, XP009006464.
Epping et al.,The Human Tumor Antigen Prame is a Dominant Repressor of Retinoic Acid Receptor Signaling, Cell, vol. 122, No. 6, Sep. 23, 2005, pp. 835-847, XP008061580. 2005.
Tajeddine et al.,Tumor-associated antigen preferentially expressed antigen of melanoma (PRAME) induces caspase-independent cell death in vitro and reduces tumorigenicity in vivo, Cancer Research, vol. 65, No. 16, Aug. 2005, pp. 7348-7355, XP002372786.
Product: sc-37322, Online Catalog of Santa Cruz Biotechnology, Inc., 2004, XP002372787.

Affiliated with

Also associated with

Rating

Combined use of PRAME inhibitors and HDAC inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Combined use of PRAME inhibitors and HDAC inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combined use of PRAME inhibitors and HDAC inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2707232